Cancer Cachexia Market Size was valued at USD 2.8 Billion in 2022. The Cancer Cachexia Market industry is projected to grow from USD 2.9 Billion in 2023 to USD 4.34 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.00% during the forecast period (2024 - 2032). The global rise in cancer prevalence, heightened awareness of cancer cachexia, and the demand for improved therapeutic solutions for individuals with cancer will boost market growth. Furthermore, the increasing elderly population and advancements in cancer research are expected to be significant market drivers for the Cancer Cachexia Market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for Cancer Cachexia is being driven by the increasing prevalence of cancer and cancer cachexia cases and the increasing investment in R&D activities for developing novel therapeutics. The global cancer burden is on the rise, necessitating the adaptation of cancer therapies based on regional and national priorities. According to the International Agency for Research on Cancer (IARC) in December 2020, 1 in 5 individuals globally developed cancer during their lifetime, with 1 in 8 men and 1 in 11 women succumbing to the disease. As per data published by the World Health Organization (WHO) in February 2022, around 400,000 children are diagnosed with cancer annually, and the most prevalent cancers vary by country, with cervical cancer ranking as the most common in 23 countries. The escalating global cancer burden correlates with a higher prevalence of cancer cachexia among patients, characterized by systemic inflammation, negative protein and energy balance, and involuntary loss of lean body mass.
In response to this, major industry players are strategically prioritizing research and development (R&D) endeavors to formulate highly effective novel drugs for cancer cachexia treatment. This dedication has resulted in an augmented pipeline of therapeutics awaiting approval and subsequent commercial launch. Notably, clinicaltrials.gov reported that, as of October 2022, a total of 150 studies were underway or completed, focusing on the development of drugs for cancer cachexia. For instance, in December 2020, the University of Copenhagen initiated a clinical study, in collaboration with Zealand University Hospital, to assess the impact of medical cannabidiol on lean body mass (cachexia) in patients undergoing Oxaliplatin- or Paclitaxel-based chemotherapy. Furthermore, in January 2021, Helsinn Group and Ono Pharmaceutical Co. Ltd received manufacturing and marketing approval for Adlumiz in Japan. Adlumiz, a ghrelin receptor agonist, is designed to address cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer, or colorectal cancer. The heightened focus on research and development activities for cancer cachexia is poised to drive market growth.
As a result, it is anticipated that throughout the projection period, demand for the Cancer Cachexia Market will increase due to the increasing prevalence of cancer and cancer cachexia cases and the increasing investment in the R&D activities for developing novel therapeutics. Thus, driving the Cancer Cachexia Market revenue.
The Cancer Cachexia Market segmentation, based on therapeutics includes progestogen, corticosteroid, combination therapy, and other therapeutics. The progestogen segment dominated the market, accounting for 58% of market revenue (1.6 Billion). Progestogens, exemplified by Medroxyprogesterone Acetate (MPA) and Megestrol Acetate (MA), presently stand out as the optimal treatment choice for cancer cachexia. They are prescribed for addressing cachexia associated with cancer and AIDS. Known for their rapid efficacy and antiemetic properties, these drugs demonstrate fast-acting relief without the common side effects like myopathy or peptic ulcer disease typically observed with corticosteroids, although high doses may lead to adrenal suppression. The substantial market share held by progestogens in the cancer cachexia segment can be attributed to factors such as their cost-effectiveness and high treatment efficiency. These factors will likely contribute significantly to maintaining the market position of the progestogens segment.
Figure 1: Cancer Cachexia Market, by Therapeutics, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Cancer Cachexia Market segmentation, based on mechanism of action includes appetite stimulators and weight loss stabilizers. The appetite stimulators segment dominated the market, accounting for 58% of market revenue (1.6 Billion). As of March 2022, the options for pharmacological interventions addressing cancer-related anorexia remain notably limited, as highlighted in a PubMed article. International guidelines advocate for the promotion of anabolism through appetite stimulants, which play a role in nutritional, physical, and pharmacological therapies. A PubMed Central article from August 2021 defines cachexia as a metabolic disturbance syndrome characterized by inflammation and the loss of muscle, with or without the loss of adipose tissue. In the context of cancer cachexia, a complex condition, patients endure weight loss and appetite reduction, significantly impacting their quality of life and overall survival. Consequently, the substantial burden of cancer cachexia on patients' quality of life is anticipated to drive increased research and development activities focused on appetite stimulators for cancer cachexia, thereby fostering growth in this segment.
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The anticipated expansion of the Cancer Cachexia market in North America can be attributed to several key factors. The United States asserts its dominance in the market due to several factors, including the high prevalence of cancer, escalating healthcare budgets, and government initiatives aimed at providing treatment options for patients facing terminal diseases. According to data from the Centers for Disease Control and Prevention, the period from 2010 to 2020 witnessed an anticipated 24% increase in new cancer cases in men, exceeding 1 million cases per year, and a 21% increase in women, surpassing 900,000 cases per year. The rising incidence of malignant cancers in the country, coupled with the well-established association between cachexia, increased mortality, and diminished well-being among patients, has garnered heightened attention, thereby fueling market growth in the United States.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: CANCER CACHEXIA MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Cancer Cachexia Market accounts for the second-largest market share as the aging demographic in Europe is particularly vulnerable to cancer, and older individuals exhibit a higher susceptibility to developing cachexia. Over the decade from 2012 to 2022, the median age in the EU experienced a notable increase of 2.5 years, averaging an annual growth of 0.25 years. This upward trend saw the median age climb from 41.9 years in 2012 to 44.4 years in 2022. Projections indicate that by 2050, the EU-27 may have close to half a million centenarians. With the continual rise in the proportion of elderly individuals, the potential prevalence of cancer cachexia is correspondingly on the ascent. Further, the German Cancer Cachexia Market held the largest market share, and the UK Cancer Cachexia Market was the fastest-growing market in the European region
The Asia-Pacific Cancer Cachexia Market is expected to grow at the fastest CAGR from 2023 to 2032. The Asia-Pacific region is experiencing progress in cancer treatment modalities and supportive care. Notably, in June 2022, the China National Medical Products Administration (NMPA) granted approval for BeiGene's anti-PD-1 antibody, tislelizumab, in combination with chemotherapy, as a first-line treatment for patients dealing with recurrent or metastatic nasopharyngeal cancer (NPC). Additionally, AstraZeneca's Imfinzi (durvalumab) received approval in China in July 2021 for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard-of-care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin). This approval reflects the region's commitment to advancing effective treatment options. As these treatment options evolve and become more efficacious, there is an increasing focus on managing cancer-related symptoms, including cachexia. Moreover, China’s Cancer Cachexia Market held the largest market share, and the Indian Cancer Cachexia Market was the fastest-growing market in the Asia-Pacific region.
Cancer Cachexia Market Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Cancer Cachexia market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Cancer Cachexia industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Cancer Cachexia industry to benefit clients and increase the market sector. In recent years, the Cancer Cachexia industry has offered some of the most significant advantages to the field of supportive oncology and the overall quality of life for cancer patients. Major players in the Cancer Cachexia Market, including Aeterna Zentaris, Aphios Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Helsinn Group, Merck KGaA, Artelo Biosciences Inc., NGM Biopharmaceuticals, Aveo Oncology, Aavogen Inc., Green Cross Wellbeing Corporation, Cannabics Pharmaceuticals Inc., TCI Peptide Therapeutics, Fresenius Kabi, Tetra Bio-Pharma, and Actimed Therapeutics are attempting to increase market demand by investing in research and development operations.
Pfizer Inc. is a prominent biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of a diverse range of products targeting conditions such as cardiovascular issues, metabolic disorders, pain management, women's health, cancer, inflammation, immune disorders, and rare diseases. The company's product portfolio includes sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs), and contract manufacturing services. Pfizer distributes its products globally through various channels, including wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies. With major manufacturing facilities strategically located worldwide, including in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the United States, Pfizer serves markets across North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. The company's headquarters is situated in New York, United States. In March 2020, Pfizer initiated a global 12-week open-label study to investigate the tolerability of its drug, PF-06946860, in patients grappling with cancer cachexia. This endeavor underscores Pfizer's commitment to advancing research and development efforts in addressing the challenges associated with cancer-related complications.
Bristol-Myers Squibb Co (BMS) is a specialized biopharmaceutical company involved in the comprehensive lifecycle of medicines, encompassing discovery, development, licensing, manufacturing, marketing, distribution, and sales. The company's core focus lies in serious diseases, with primary therapeutic projects concentrated in cancer, cardiovascular, immunology, and fibrotic areas. BMS extends its product offerings globally, catering to wholesalers, retail pharmacies, medical professionals, hospitals, and government entities, with a presence in the US, Europe, and Japan. Headquartered in New York City, New York, BMS is at the forefront of research, dedicated to discovering and developing innovative medicines that address critical diseases in areas characterized by substantial unmet medical needs. Notably, BMS actively participates in the development of therapies for cancer cachexia, aligning with its position as a leading global biopharmaceutical entity renowned for its diverse portfolio of cancer treatments. While the specific revenue generated from cancer cachexia products is not publicly disclosed, BMS reported a total revenue of $ billion in the fiscal year 2020, underscoring its significant presence and financial standing in the industry.
Key companies in the Cancer Cachexia Market include
Cancer Cachexia Industry Developments
August 2022: In August 2022, ARTHEx biotech introduced ENTRYTM, a platform designed to propel its drug pipeline, which encompasses treatments for myotonic dystrophy, cancer cachexia, and osteoarthritis. This platform facilitates tissue-enriched delivery of antimiRs.
June 2022: In June 2022, a team led by the Rutgers Cancer Institute of New Jersey secured a $25 million Cancer Grand Challenges grant to research cancer cachexia, a debilitating condition frequently encountered in the advanced stages of cancer.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 2.8 Billion |
| Market Size 2023 | USD 2.9 Billion |
| Market Size 2032 | USD 4.34 Billion |
| Compound Annual Growth Rate (CAGR) | 5.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Therapeutics, Mechanism of Action, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Aeterna Zentaris, Aphios Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Helsinn Group, Merck KGaA, Artelo Biosciences Inc., NGM Biopharmaceuticals, Aveo Oncology, Aavogen Inc., Green Cross Wellbeing Corporation, Cannabics Pharmaceuticals Inc., TCI Peptide Therapeutics, Fresenius Kabi, Tetra Bio-Pharma, and Actimed Therapeutics |
| Key Market Opportunities | ·      Development of Effective Therapeutics for the Treatment of Target Diseases |
| Key Market Dynamics | ·      Use of a multidisciplinary approach and development of combined therapies |
Frequently Asked Questions (FAQ) :
The Cancer Cachexia Market size was valued at USD 2.8 Billion in 2022.
The Cancer Cachexia Market is projected to grow at a CAGR of 5.00% during the forecast period, 2024-2032.
North America had the largest share of the global market
The key players in the market are Aeterna Zentaris, Aphios Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Helsinn Group, Merck KGaA, Artelo Biosciences Inc., NGM Biopharmaceuticals, Aveo Oncology, Aavogen Inc., Green Cross Wellbeing Corporation, Cannabics Pharmaceuticals Inc., TCI Peptide Therapeutics, Fresenius Kabi, Tetra Bio-Pharma, and Actimed Therapeutics.
The progestogen segment dominated the market in 2022.
The appetite stimulators segment had the largest share of the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
